These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
730 related articles for article (PubMed ID: 20392868)
1. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868 [TBL] [Abstract][Full Text] [Related]
2. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846 [TBL] [Abstract][Full Text] [Related]
3. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499 [TBL] [Abstract][Full Text] [Related]
4. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272 [TBL] [Abstract][Full Text] [Related]
5. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824 [TBL] [Abstract][Full Text] [Related]
6. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694 [TBL] [Abstract][Full Text] [Related]
7. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257 [TBL] [Abstract][Full Text] [Related]
8. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation. Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300 [TBL] [Abstract][Full Text] [Related]
10. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638 [TBL] [Abstract][Full Text] [Related]
11. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH. Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143 [TBL] [Abstract][Full Text] [Related]
12. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781 [TBL] [Abstract][Full Text] [Related]
13. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565 [TBL] [Abstract][Full Text] [Related]
14. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005 [TBL] [Abstract][Full Text] [Related]
15. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. Rosário PW; Borges MA; Purisch S J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337 [TBL] [Abstract][Full Text] [Related]
16. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234 [TBL] [Abstract][Full Text] [Related]
17. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259 [TBL] [Abstract][Full Text] [Related]
18. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246 [TBL] [Abstract][Full Text] [Related]
19. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Rosario PW; Calsolari MR Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908 [TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose. Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]